Miruvor
Sign up
The short answer

What studies of homeopathy found

24papers on homeopathy
60people in 2 studies testing homeopathy alone
2randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, the randomised trial (very low certainty): 3 findings, all C.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Homeopathy might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 24 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Homeopathy · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue1 study · 30 people took homeopathy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (60 in all).

The randomised trial60 randomised · every month, for up to 3 months

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of homeopathy on fatigue in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (60 in all)

Combination: Homeopathy104 in the study

[Asthenic post-COVID syndrome]. (2023): general asthenia severity, no clear difference.

Shown, not counted: homeopathy was given together with other treatments.

See the 1 study
  1. Individualized Homeopathic Medicines in the Treatment of Post-COVID-19 Fatigue in Adults: Single-Blind, Randomized, Placebo-Controlled Trial. (2024)

    People in the study
    60 randomised
    Dose
    —
    Outcome
    Fatigue Assessment Scale (FAS) total Fatigue Assessment Scale
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    High

Daily life and health overall

Daily functioning1 study · 30 people took homeopathy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (60 in all).

The randomised trial60 randomised · every month, for up to 3 months

Daily functioning improved more than in the comparison group.

The evidence is very uncertain about the effect of homeopathy on daily functioning in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (60 in all)
See the 1 study
  1. Individualized Homeopathic Medicines in the Treatment of Post-COVID-19 Fatigue in Adults: Single-Blind, Randomized, Placebo-Controlled Trial. (2024)

    People in the study
    60 randomised
    Dose
    —
    Outcome
    Outcome in Relation to Impact on Daily Living (ORIDL) Outcome in Relation to Impact on Daily Living
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    High
Overall symptoms1 study · 30 people took homeopathy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (60 in all).

The randomised trial60 randomised · at baseline, and monthly intervals, up to 3 months

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of homeopathy on overall symptoms in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (60 in all)
See the 1 study
  1. Individualized Homeopathic Medicinal Products in the Treatment of Post-COVID-19 Conditions: A Double-Blind, Randomized, Placebo-Controlled, Feasibility Trial. (2025)

    People in the study
    60 randomised
    Dose
    —
    Outcome
    post-COVID-19 symptoms checklist
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    High

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. A randomised, controlled, triple-blind trial of the efficacy of homeopathic treatment for chronic fatigue syndrome.2004 · placebo trial · 103 randomised · 86 analysed
    Summary

    This randomised, controlled, triple-blind trial evaluated homeopathic treatment for chronic fatigue syndrome (CFS) in patients meeting the Oxford criteria. Patients over 18 years old were recruited from two hospital outpatient departments in the UK; a consecutive series of 103 patients was randomised. Patients received homeopathic medicine or identical placebo, with monthly consultations with a professional homeopath for 6 months; follow-up was 7 months after the end of randomisation. Primary outcomes were the five Multidimensional Fatigue Inventory (MFI) subscales and proportions attaining clinically significant improvement; secondary outcomes were the Fatigue Impact Scale (FIS) and Functional Limitations Profile (FLP). Eighty-six patients returned fully or partially completed posttreatment outcome measures, with 43 in each arm in the reported tables. The homeopathic medicine group showed significantly more improvement on MFI general fatigue (mean change 2.70 vs 1.35; P = .04) and FLP physical dimension (5.11 vs 2.72; P = .04), but not on other MFI subscales or other secondary outcomes. Clinically significant improvement on all primary outcomes occurred in 11/43 with homeopathic medicine and 4/43 with placebo (relative risk = 2.75, P = .09). Seventeen of 103 patients withdrew from treatment or were lost to follow-up; six homeopathic and five placebo patients did not complete 6 months. Side effects were not reported.

  2. Individualized Homeopathic Medicinal Products in the Treatment of Post-COVID-19 Conditions: A Double-Blind, Randomized, Placebo-Controlled, Feasibility Trial.2025 · randomised trial · 60 randomised
    Summary

    This double-blind, randomized, placebo-controlled feasibility trial took place at D. N. De Homoeopathic Medical College & Hospital, Kolkata, West Bengal, India, in people with post-COVID-19 conditions. Sixty participants were enrolled. Group verum (n = 30; IHMPs plus concomitant care) was compared with group control (n = 30; placebos plus concomitant care). Outcomes were the post-COVID-19 symptoms checklist (primary) and MYMOP-2 (secondary), measured at baseline and monthly intervals, up to 3 months. The intention-to-treat sample was analyzed. Feasibility concerns showed promise; recruitment, retention, and attrition rates were 34.2%, 95%, and 5%, respectively. Group differences in both primary and secondary outcomes favored IHMPs against placebos: symptoms checklist score mean difference after 3 months: −4.2, 95% CI −4.9 to −3.4, d = 2.854; MYMOP-2 mean difference after 3 months: −2.2, 95% CI −2.8 to −1.7, d = 2.082. The text did not report a no-difference result, worsening, or stopping. The paper did not report side effects, harms, or withdrawals.

  3. Individualized Homeopathic Medicines in the Treatment of Post-COVID-19 Fatigue in Adults: Single-Blind, Randomized, Placebo-Controlled Trial.2024 · randomised trial · 60 randomised
    Summary

    This 3-month, single-blind, randomized, placebo-controlled, parallel-arm trial was conducted at the outpatient department of The Calcutta Homoeopathic Medical College and Hospital, India. Sixty adults with post-COVID-19 fatigue were randomized to receive either individualized homeopathic medicines (IHMs) (n = 30) or identical-looking placebos (n = 30). The primary outcome was the Fatigue Assessment Scale (FAS) and the secondary outcome was Outcome in Relation to Impact on Daily Living (ORIDL), measured every month, for up to 3 months. Comparative analysis was carried out on the intention-to-treat sample. After 3 months, group differences in both outcomes favored IHMs against placebos: FAS total F1, 58 = 14.356, p < 0.001; ORIDL F1, 58 = 210.986, p < 0.001. No harm, unintended effects, homeopathic aggravations, or any serious adverse events were reported from either of the groups. The authors concluded that IHMs produced significantly better effects than placebos and stated that definitive robust trials may be undertaken to confirm the findings. No other limitations were stated in the text.

  4. Towards standard setting for patient-reported outcomes in the NHS homeopathic hospitals.2008 · no comparison group · 1,797 in the study
    Summary

    This pilot data collection study took place in five NHS homeopathic hospital outpatient clinics over a 4-week period, with 51 medical practitioners recording consecutive appointments. Data were recorded on a total of 1797 individual patients: 195 first appointments and 1602 follow-ups. The paper reports a mixed outpatient population; the four most frequently treated complaints were eczema, chronic fatigue syndrome (CFS), menopausal disorder and osteoarthritis. Patients received homeopathy; duration was not reported. There was no comparison group. Outcomes were patient-reported change using ORIDL and its ORIDL Profile Score (ORIDL-PS). Among all medical complaints, 34.5% of patients at appointment 2, 59.3% at appointment 6 and 67.0% at more than 6 appointments reported ORIDL-PS $ +2 (health benefit affecting daily living). At more than 6 appointments, 59.3% of CFS patients and 73.3% of menopausal disorder patients reported ORIDL-PS $ +2. Health deterioration (ORIDL-PS < 0) averaged about 3% of patients per visit number; CFS patients included 10.0% at appointment 3, 12.5% at appointment 4 and 4.9% at more than 6 appointments. Withdrawals due to harms were not reported. Two records were excluded altogether. The authors state that an observational study of this nature has no reference group of patients to serve as controls and that a causal relationship between homeopathy and reported outcome cannot be attributed from the data.

  5. A multidimensional treatment plan for chronic fatigue syndrome1999 · no comparison group · 81 in the study · 64 with outcome data
    Summary

    This pilot study without a control group assessed a cumulative multidimensional treatment plan in 81 patients with chronic fatigue syndrome fulfilling Oxford criteria, referred to the Glasgow Homoeopathic Hospital. Treatment was added monthly over 6 months: a wheat-free diet with nutritional supplements, then homoeopathic treatment of allergies, then homoeopathic constitutional remedies, then psychotherapeutic techniques for self-image and inner resources. Outcomes were clinical evaluation and six questionnaires. Sixty-four patients completed the study. Of these, 45 (70%) reported clinical improvement with a positive effect on daily living; the same patients reported improvement in the six questionnaire scores, apart from 4 patients who did not improve their scores in two tests. No patient deteriorated. Mean monthly questionnaire scores declined steadily over the first four months and then steadied; scores after 4 months were significantly lower than on entry for the group as a whole and for the allergic, non-allergic and female subgroups, but not for the men. More women improved than men (38/51 versus 7/13), a difference reported as not quite significant. Patients with and without allergies were reported to improve to the same extent. Seventeen patients dropped out: 2 could not organize the wheat-free diet, 1 was a baker, 2 withdrew on religious grounds related to the ego-strengthening exercises, 4 improved but did not complete, and the reasons for the remaining 8 were not ascertained. The authors call for a randomized controlled trial.

  6. Exploring the Role of Homeopathic Intervention in Post-COVID Functional Gastrointestinal Disorders: A Case Series of 12 Patient Profiles.2025 · case report · 12 in the study
    Summary

    This retrospective case series asked whether individualized homeopathic medicines help post-COVID functional gastrointestinal disorders (PC-FGIDs). Twelve patients were included according to the study criteria and treated exclusively with individualized homeopathic medicines for a 3-month treatment period. There was no comparison group. The paper reports that cases had regular monthly assessment using the Gastrointestinal Symptoms Rating Scale (GSRS) and a Post-COVID-19 Functional Status (PCFS) score for up to 3 months. GSRS and PCFS scores showed marked improvement in each of 10 cases within the 3-month treatment period; the authors conclude that homeopathic intervention proved beneficial in 10 of 12 patients with PC-FGIDs. No between-group comparison was reported. The text does not report worsening or stopping treatment. Side effects were not reported, and the paper does not report any withdrawals for harms. The authors state that the findings may help researchers plan future controlled clinical studies in this field.

  7. Homeopathic treatment of Chronic Fatigue Syndrome: three case studies using Jan Scholten's methodology.2002 · case report · 3 in the study
    Summary

    This paper reports three case studies from a homeopathic practice of people with Chronic Fatigue Syndrome (CFS), or Myalgic Encephalomyelitis (ME), following glandular fever. Three patients are presented: Jane, age 19; Susan, age 19; and Mike, age 31. No comparison group, randomisation, crossover or blinding is reported. Jane received Cobaltum phosphoricum 1M, 3 doses, 12h apart. Susan received Calcium phosphoricum 200C, 3 doses. Mike received a series of remedies, including Cadmium Phosphoricum 200C, 3 doses. Outcomes were patient-reported symptoms and functioning at follow-up; no fixed treatment duration is reported. Jane reported being more alert and brighter at 2 months, a good night’s sleep, less cystitis, less crying, and a full-time job; later she was very well at 22 months and thought homeopathy worked a miracle. Susan reported feeling better within two weeks, happier and enjoying university at 1 month, feeling a lot better and physical fatigue lifted at 3 months. Mike reported that Phosphorus did not have much effect at 3 months, felt a bit better at 4 months, aching pains improved at 7 months, and after Cadmium Phosphoricum reported the remedy made a difference, felt 60% better, and felt 75% better by April 1999; by 2000 he felt completely well. Harms included feeling ill after the remedy, a slight reaction with a sore throat for a week, and feeling worse for two weeks after taking the remedy with bad aches and a sore throat.

  8. [Asthenic post-COVID syndrome].2023 · combination: given with other treatments · 104 in the study
    Summary

    This study evaluated a combination therapy for post-COVID asthenic syndrome in 104 patients (averaged age 39.5 [30.8; 48] years) after COVID-19, clinically recovered from an acute infectious process, with asthenia lasting from 2 weeks to 6 months and asthenia VAS at least 30 points. Patients in the main group received Traumeel S 1 tablet x 3 times a day plus Ubichinone compositum and Coenzyme compositum 2.2 ml intramuscularly, alternating every other day, for 1 month (15 injections of each drug per course). The comparison group received eleutherococcus extract 100 mg during 30 days, 2 tablets x 2 times a day before meals, and vitamins B. Assessments included asthenia VAS, MFI-20, L.D. Malkova scale, EQ-5D, and Vayne questionnaire, with follow-up visits 2 weeks, 1 month after start, and 1 month after end of treatment. General asthenia severity, low activity, and motivation significantly decreased in both groups without significant differences. In the comparison group there was no correlation between quality of life and physical and mental asthenia; in the main group there was an inverse correlation with asthenia severity, indicating increased quality of life with decreased asthenia severity. Significant differences included regression of headache and musculoskeletal pain in the main group. Side effects and withdrawals were not reported. The abstract does not state limitations.

  9. Chronic Fatigue Syndrome: Do herbs or homeopathy help?1992 · combination: given with other treatments · 6 in the study
    Summary

    This study was done to determine the effect of certain herbal and homeopathic preparations on symptoms, lymphocyte markers, and cytotoxic function of the lymphocytes in patients with chronic fatigue syndrome. Six outpatients diagnosed by their family physicians took part. After a 3-week symptom-recording period, patients were given herbal and homeopathic preparations; the abstract does not report the dose, route, schedule, or how long treatment continued. Symptoms were recorded again after treatment, and blood samples were taken before and after treatment. There was no comparison group, so the report describes before-and-after observations in the same patients rather than a comparison with placebo or another treatment. The abstract reports that none of the values showed any significant change after treatment. It does not report how many patients were analysed, whether anyone worsened or stopped treatment, or any side effects. The authors do not state a separate conclusion or limitations in the abstract; the only stated finding is the absence of significant change after treatment.

  10. A mixed-methods systematic review of post-viral fatigue interventions: Are there lessons for long Covid?2021 · systematic review
    Summary

    This mixed-methods systematic review asked whether post-viral fatigue interventions offer lessons for long Covid. Online databases were searched in October 2020, and 40 papers were selected. The included fatigue interventions involved 25 studies in CFS/ME, nine in fibromyalgia and eight in unexplained fatigue. Treatments varied widely and were compared with controls, typically usual care or waiting lists; fatigue severity was the main outcome. Intervention duration varied and is not quantified in the recorded data. The review reported mean differences for several interventions. The largest mean difference was for the Three Principles/Innate Health programme (MD -39.0, 95% CI -51.8 to -26.2, SMD = 1.670). Group-based CBT also showed reductions (MD -27.5, 95% CI -33.7 to -21.3, SMD = 1.170; MD -23.7, 95% CI -29.2 to -18.2, SMD = 2.266). Smaller mean differences were reported for GET (MD -11.5, 95% CI -17.6 to -5.4, SMD = 0.524) and self-regulation based physical activity (MD -9.9, 95% CI -16.3 to -3.4, SMD = 0.513). TENS (MD -6.0, 95% CI -16.9 to 4.9, SMD = 0.239), Tai Ji Quan (MD -0.4, 95% CI -9.6 to 8.9, SMD = 0.023) and supportive listening (MD 1.06, 95% CI -1.4 to 3.6, SMD = -0.111) showed little or no benefit. Doxycycline mean differences were positive (MD 6.3, 95% CI 3.7 to 8.8, SMD = -0.752; MD 8.75, 95% CI 6.36 to 11.14, SMD = -1.120). No side effects, withdrawals or worsening were reported in the recorded data.

  11. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.2015 · systematic review
    Summary

    This systematic review examined treatments for adults with ME/CFS. It included 35 treatment trials in 45 publications; trials enrolled predominantly middle-aged women from ME/CFS specialty clinics and used CFS case definitions. Treatments were compared with placebo, usual care, wait-list, relaxation, adaptive pacing, CBT, or other therapies. In 2 fair-quality trials (n=324), rintatolimod improved cardiopulmonary exercise test tolerance (36.5% versus 15.2%; P=0.047), exercise duration (10.3% versus 2.1%; P=0.007), and exercise work (11.8% versus 5.8%; P=0.01). In a small trial of 30 participants, valganciclovir improved fatigue on 1 scale but showed no statistically significant differences for other measures. Trials of galantamine, hydrocortisone, IgG, isoprinosine, and fluoxetine indicated no beneficial effects but were limited by small numbers. Counseling and behavior therapies improved fatigue, function, quality of life, work impairment, and global improvement in some trials (low to moderate strength of evidence). A meta-analysis of 4 CBT trials found no statistically significant difference in SF-36 physical function (weighted mean difference, 10.42 [95% Cl, -3.86 to 24.69]); a sensitivity analysis found 6.02 [Cl, 1.05 to 10.88]. GET improved function (10.68 [Cl, 6.32 to 16.88]), fatigue (4 trials, n=619), and global improvement (relative risk, 1.58 [Cl, 1.24 to 2.47]). In the PACE trial, deterioration of physical function was 25% with adaptive pacing, 18% with usual care, and 11% with GET (P<0.001). Harms included galantamine: 90% reported harms and 2% serious events, none attributed to study drug; IgG headaches 93% versus 60%; GET serious adverse events 17 versus 7. GET withdrawals were 37% versus 22%, and 20% declined repeat exercise testing. Adverse effects were rarely reported overall.

  12. Chronic fatigue syndrome.2011 · systematic review
    Summary

    This systematic review asked what the effects of treatments for chronic fatigue syndrome are. The authors searched Medline, Embase, The Cochrane Library and other databases up to March 2010, included 46 systematic reviews, RCTs or observational studies, and rated the quality of the evidence with GRADE. They list the treatments covered: antidepressants, cognitive behavioural therapy, corticosteroids, dietary supplements, evening primrose oil, galantamine, graded exercise therapy, homeopathy, immunotherapy, intramuscular magnesium, oral nicotinamide adenine dinucleotide and prolonged rest. The abstract gives no finding for any of them and names no included study, so no results are listed here.

  13. Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies.2011 · systematic review
    Summary

    This systematic review asked whether placebo-controlled randomized trials of homeopathy show effects in psychiatric conditions. The authors identified twenty-five eligible studies from an initial pool of 1,431, searching databases from database inception to April 2010. Identified studies were grouped into anxiety or stress, sleep or circadian rhythm complaints, premenstrual problems, attention-deficit/hyperactivity disorder, mild traumatic brain injury, and functional somatic syndromes. Treatments concerned homeopathy compared with placebo; treatment duration was not reported. The review reported that efficacy was found for the functional somatic syndromes group (fibromyalgia and chronic fatigue syndrome), but not for anxiety or stress; for other disorders, homeopathy produced mixed effects. Effect size could be calculated in 16 studies, and number needed to treat, in 10 studies. Study quality varied, with 6 assessed as good, 9 as fair, and 10 as poor, and outcome was unrelated to SIGN quality. Meaningful safety data were lacking in the reports, but the superficial findings suggested good tolerability of homeopathy. A funnel plot in 13 studies did not support publication bias (χ(2)(1) = 1.923, P = .166). The authors state the database is very limited, but results do not preclude the possibility of some benefit. Counts of people who worsened or stopped were not reported.

  14. Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review.2011 · systematic review
    Summary

    This systematic review examined randomised controlled trials of complementary and alternative medicine (CAM) for patients with chronic fatigue syndrome (CFS), also termed myalgic encephalomyelitis (ME). The search was up to 13th August 2011. A total of 26 RCTs, which included 3,273 participants, met the inclusion criteria. The CAM therapies included mind-body medicine, distant healing, massage, tuina and tai chi, homeopathy, ginseng, and dietary supplementation. The review reports that studies of qigong, massage and tuina demonstrated positive effects, whereas distant healing failed to show a significant effect on mental or physical components of quality of life. Compared with placebo, homeopathy had insufficient evidence of symptom improvement in CFS. Most supplements failed to show beneficial effects for CFS, with the exception of NADH and magnesium. Five of the 26 included studies reported no adverse events or a slight occurrence of them, and the other included studies lacked descriptions regarding adverse events; no severe adverse effects of CAM were noted. The authors state that firm conclusions are difficult with the limited number of RCTs for each therapy, small sample sizes and high risk of bias.

  15. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia.2010 · systematic review
    Summary

    The review included 70 controlled clinical trials of alternative and complementary treatments and nonpharmacological supplements for ME/CFS and fibromyalgia; searches ran up to April 2007. It did not have its own treatment arm or comparison group; it summarized trials with control or comparison conditions. The review did not report one treatment dose or duration. Outcomes in included trials covered laboratory tests, physical functioning, psychologic functioning, and quality of life. The review reports that some trials showed at least one positive effect and some showed null or ambiguous results; it states that no firm conclusions can be made. Only three studies (4%) reported adverse side-effects such as bruising and rashes. For acupuncture, three RCTs reported dropout rates of around 15%–35% in all intervention groups. The authors state publication bias: beneficial effects tend to be published while negative results may remain unpublished. They also state the methodological quality of reporting was generally poor and that no definite CAM treatment recommendations can be made for ME/CFS or FM.

  16. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
    Summary

    This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.

  17. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
    Summary

    This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).

  18. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  19. Exploring the scope of homoeopathy in combating the unfortunate consequences of post-COVID-19 survivors based on non-COVID conditions: a narrative review.2023 · review
    Summary

    This narrative review asked whether homoeopathy can help COVID-19 survivors recover from post-COVID consequences and improve quality of life. The authors searched PubMed/MEDLINE and references of published articles; 61 studies included for this review. The paper reports no study population size, setting, duration, comparison group, randomisation, or analysed participant count. Homoeopathy was the treatment discussed, with no comparator reported. The review states that outcomes for Chronic Fatigue Syndrome (CFS), Influenza, and Acute Respiratory Tract Infections (ARTIs) are promising, and that homoeopathy can be thought of in the management of post-COVID-19 outcomes. It proposes that homoeopathic management may be included as part of the follow-up route for post-COVID-19 patient rehabilitation. CFS is mentioned among outcomes, not as a study population. No side effects, harms, worsening, or withdrawals are reported. The authors state that the long-term consequences of COVID-19 survivors care and post-coronavirus infection are not yet well understood. They conclude that homoeopathy can be thought of in the management of post-COVID-19 outcomes.

  20. Management of chronic fatigue syndrome/myalgic encephalomyelitis in a pediatric population: A scoping review.2020 · review
    Summary

    This scoping review examined peer-reviewed research on managing chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a pediatric population aged under 18 years. The authors searched electronic databases and included 29 peer-reviewed research articles; no new participants were enrolled. The review grouped findings under nutrition/dietary components, exercise therapy, psychosocial factors, and multifaceted treatment. Included studies evaluated CBT with biofeedback, the Lightning Process plus standard medical care, aerobic graded exercise versus progressive resistance training, graded activity/exercise with family sessions, dietary changes, pacing versus STAIRway to Health, and other programs. Outcomes included fatigue severity, school attendance, physical function, anxiety and depression, quality of life, and global health. The review reports that included studies found lower fatigue severity and higher school attendance with CBT plus biofeedback, improvement with Lightning Process plus standard medical care, and no significant difference between aerobic graded exercise and progressive resistance training for physical capacity and QOL, while fatigue and depressive symptoms improved only in the aerobic group. No harms, side effects, worsening or withdrawals were reported in the recorded data. The authors state a lack of research in younger children and insufficient evidence for dietary modifications or supplements in prepubescent children.

  21. PACE investigators' response is misleading regarding patient survey results.2017 · review
    Summary

    This Open Peer Commentary Article reviews patient survey data published between 2001 and 2015 on ME/CFS. Five major patient surveys by Action for ME and The ME Association are pooled. Surveys asked patients about availability, helpfulness, improvement, worsening, or disability benefits for therapies including GET, CBT and pacing. In Action for ME 2011a (977 respondents), 48 per cent responded ‘yes’ for GET and 66 per cent for CBT being available on the NHS, compared with 90–94 per cent for pacing, medications and fatigue/condition management. In The ME Association 2010 survey (3099 respondents), 82 per cent wanted pacing, 28 per cent CBT and 24 per cent GET. In The ME Association 2010 survey (n = 4217), 22 per cent reported improvement with GET, 26 per cent with CBT and 71 per cent with pacing; 57 per cent reported worse symptoms from GET, 20 per cent from CBT and 5 per cent from pacing. The ME Association 2015 reported a net increase in patients on disability benefits after GET courses (+13%) and CBT courses (+10%), compared with a net decrease after pacing courses (−1%). The author states survey limitations should be borne in mind.

  22. Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
    Summary

    The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.

  23. Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
    Summary

    This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime